BSX icon

Boston Scientific

99.36 USD
-1.44
1.43%
At close Mar 28, 4:00 PM EDT
After hours
99.36
+0.00
0.00%
1 day
-1.43%
5 days
-2.32%
1 month
-4.27%
3 months
10.79%
6 months
18.57%
Year to date
11.17%
1 year
45.07%
5 years
214.03%
10 years
449.86%
 

About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Employees: 53,000

0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

144% more first-time investments, than exits

New positions opened: 207 | Existing positions closed: 85

24% more repeat investments, than reductions

Existing positions increased: 600 | Existing positions reduced: 482

11% more funds holding in top 10

Funds holding in top 10: 35 [Q3] → 39 (+4) [Q4]

8% more capital invested

Capital invested by funds: $111B [Q3] → $120B (+$8.61B) [Q4]

7% more funds holding

Funds holding: 1,372 [Q3] → 1,470 (+98) [Q4]

0.43% more ownership

Funds ownership: 90.07% [Q3] → 90.5% (+0.43%) [Q4]

13% less call options, than puts

Call options by funds: $797M | Put options by funds: $912M

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$115
16%
upside
Avg. target
$120
21%
upside
High target
$130
31%
upside

9 analyst ratings

positive
100%
neutral
0%
negative
0%
Stifel
Rick Wise
41% 1-year accuracy
14 / 34 met price target
21%upside
$120
Buy
Maintained
10 Feb 2025
Barclays
Matt Miksic
59% 1-year accuracy
24 / 41 met price target
19%upside
$118
Overweight
Maintained
10 Feb 2025
UBS
Danielle Antalffy
38% 1-year accuracy
5 / 13 met price target
31%upside
$130
Buy
Maintained
7 Feb 2025
Raymond James
Jayson Bedford
60% 1-year accuracy
15 / 25 met price target
23%upside
$122
Strong Buy
Maintained
6 Feb 2025
RBC Capital
Shagun Singh
60% 1-year accuracy
40 / 67 met price target
17%upside
$116
Outperform
Maintained
6 Feb 2025

Financial journalist opinion

Based on 18 articles about BSX published over the past 30 days

Positive
Zacks Investment Research
3 days ago
International Expansion, Product Launches Support BSX Stock
Boston Scientific continues to successfully expand its operations across various geographies outside the United States.
International Expansion, Product Launches Support BSX Stock
Positive
Investors Business Daily
5 days ago
Medical Products Leader Tops These Early-Bird Buy Points
Boston Scientific has the highest Composite Rating of 126 companies in the medical products industry. The post Medical Products Leader Tops These Early-Bird Buy Points appeared first on Investor's Business Daily.
Medical Products Leader Tops These Early-Bird Buy Points
Neutral
Zacks Investment Research
5 days ago
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic
Boston Scientific, Abbott and Medtronic are included in this Analyst Blog.
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic
Neutral
Zacks Investment Research
6 days ago
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.67, denoting a +1.97% change from the preceding trading day.
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
Negative
Zacks Investment Research
6 days ago
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy
Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025.
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy
Positive
Zacks Investment Research
6 days ago
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Positive
Investors Business Daily
1 week ago
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait
GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily.
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait
Positive
Zacks Investment Research
2 weeks ago
PAHC vs. BSX: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
PAHC vs. BSX: Which Stock Should Value Investors Buy Now?
Positive
Zacks Investment Research
2 weeks ago
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
Positive
Zacks Investment Research
2 weeks ago
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Charts implemented using Lightweight Charts™